PMC:7212965 / 43712-43920 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T101","span":{"begin":137,"end":152},"obj":"Body_part"},{"id":"T102","span":{"begin":198,"end":208},"obj":"Body_part"}],"attributes":[{"id":"A101","pred":"fma_id","subj":"T101","obj":"http://purl.org/sig/ont/fma/fma317863"},{"id":"A102","pred":"fma_id","subj":"T102","obj":"http://purl.org/sig/ont/fma/fma78440"}],"text":"ir in COVID-19. The first is an open-label RCT for favipiravir vs arbidol conducted in Wuhan, China by Chen et al.92 This study reported digestive tract reactions, including nausea, “anti-acid,” or flatulence"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T77","span":{"begin":137,"end":152},"obj":"Body_part"}],"attributes":[{"id":"A77","pred":"uberon_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/UBERON_0001555"}],"text":"ir in COVID-19. The first is an open-label RCT for favipiravir vs arbidol conducted in Wuhan, China by Chen et al.92 This study reported digestive tract reactions, including nausea, “anti-acid,” or flatulence"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T226","span":{"begin":6,"end":14},"obj":"Disease"}],"attributes":[{"id":"A226","pred":"mondo_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"ir in COVID-19. The first is an open-label RCT for favipiravir vs arbidol conducted in Wuhan, China by Chen et al.92 This study reported digestive tract reactions, including nausea, “anti-acid,” or flatulence"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T330","span":{"begin":37,"end":42},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T331","span":{"begin":137,"end":152},"obj":"http://purl.obolibrary.org/obo/UBERON_0001555"}],"text":"ir in COVID-19. The first is an open-label RCT for favipiravir vs arbidol conducted in Wuhan, China by Chen et al.92 This study reported digestive tract reactions, including nausea, “anti-acid,” or flatulence"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T109","span":{"begin":37,"end":42},"obj":"Chemical"},{"id":"T110","span":{"begin":51,"end":62},"obj":"Chemical"},{"id":"T111","span":{"begin":66,"end":73},"obj":"Chemical"},{"id":"T112","span":{"begin":188,"end":192},"obj":"Chemical"}],"attributes":[{"id":"A109","pred":"chebi_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A110","pred":"chebi_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A111","pred":"chebi_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A112","pred":"chebi_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"}],"text":"ir in COVID-19. The first is an open-label RCT for favipiravir vs arbidol conducted in Wuhan, China by Chen et al.92 This study reported digestive tract reactions, including nausea, “anti-acid,” or flatulence"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T201","span":{"begin":174,"end":180},"obj":"Phenotype"}],"attributes":[{"id":"A201","pred":"hp_id","subj":"T201","obj":"http://purl.obolibrary.org/obo/HP_0002018"}],"text":"ir in COVID-19. The first is an open-label RCT for favipiravir vs arbidol conducted in Wuhan, China by Chen et al.92 This study reported digestive tract reactions, including nausea, “anti-acid,” or flatulence"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1206","span":{"begin":51,"end":62},"obj":"Chemical"},{"id":"1207","span":{"begin":66,"end":73},"obj":"Chemical"},{"id":"1211","span":{"begin":6,"end":14},"obj":"Disease"},{"id":"1212","span":{"begin":174,"end":180},"obj":"Disease"},{"id":"1213","span":{"begin":198,"end":208},"obj":"Disease"}],"attributes":[{"id":"A1206","pred":"tao:has_database_id","subj":"1206","obj":"MESH:C462182"},{"id":"A1207","pred":"tao:has_database_id","subj":"1207","obj":"MESH:C086979"},{"id":"A1211","pred":"tao:has_database_id","subj":"1211","obj":"MESH:C000657245"},{"id":"A1212","pred":"tao:has_database_id","subj":"1212","obj":"MESH:D009325"},{"id":"A1213","pred":"tao:has_database_id","subj":"1213","obj":"MESH:D005414"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ir in COVID-19. The first is an open-label RCT for favipiravir vs arbidol conducted in Wuhan, China by Chen et al.92 This study reported digestive tract reactions, including nausea, “anti-acid,” or flatulence"}